Quest Diagnostics (DGX) Reports In-Line Q2 EPS, Slight Revenue Miss; Narrows FY18 EPS Outlook, Lowers FY18 Revenue Mid-Point Guidance

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $1.75, in-line with the analyst estimate of $1.75. Revenue for the quarter came in at $1.91 billion versus the consensus estimate of $1.95 billion.

"Once again, we grew revenues and delivered strong earnings growth in the second quarter,\" said Steve Rusckowski, Chairman, President and CEO. "We continue to strengthen our strategic relationship with UnitedHealth Group and are excited to serve as a national in-network lab provider for UnitedHealthcare members beginning January 1, 2019. Overall, we remain focused on delivering on our two-point strategy and have updated our outlook for the full-year 2018 to reflect our confidence in achieving our commitments for the year."

GUIDANCE:

Quest Diagnostics sees FY2018 EPS of $6.53-$6.67, versus the consensus of $6.61. Quest Diagnostics sees FY2018 revenue of $7.7-7.74 billion, versus the consensus of $7.72 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
• Quest Diagnostics (DGX) PT Raised to $155 at Mizuho